Sharkey, Howes & Javer’s Teva Pharmaceuticals TEVA Stock Holding History

Sharkey, Howes & Javer’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-750	Closed	-$7K	–	158
2019 Q2	$7K	Hold	750	–	–	﹤0.01%	163
2019 Q1	$12K	Hold	750	–	–	0.01%	151
2018 Q4	$12K	Hold	750	–	–	0.01%	148
2018 Q3	$16K	Hold	750	–	–	0.01%	150
2018 Q2	$18K	Hold	750	–	–	0.01%	145
2018 Q1	$12K	Hold	750	–	–	0.01%	144
2017 Q4	$14K	Sell	750 -900	-55%	-$13.5K	0.01%	141
2017 Q3	$26K	Hold	1,650	–	–	0.01%	118
2017 Q2	$55K	Hold	1,650	–	–	0.03%	79
2017 Q1	$53K	Hold	1,650	–	–	0.03%	88
2016 Q4	$60K	Sell	1,650 -358	-18%	-$14.3K	0.04%	84
2016 Q3	$92K	Hold	2,008	–	–	0.06%	64
2016 Q2	$101K	Buy	2,008 +358	+22%	+$19.1K	0.06%	64
2016 Q1	$88K	Hold	1,650	–	–	0.06%	68
2015 Q4	$108K	Hold	1,650	–	–	0.08%	53
2015 Q3	$105K	Hold	1,650	–	–	0.08%	52
2015 Q2	$98K	Hold	1,650	–	–	0.07%	42
2015 Q1	$103K	Buy	+1,650	New	+$95.9K	0.07%	65

Other funds holding TEVA

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Berkshire Hathaway Omaha, Nebraska $299B AUM 27.55% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

ACM

Abrams Capital Management Boston, Massachusetts $5.48B AUM 3.63% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Commerzbank Aktiengesellschaft Frankfurt, Germany $5B AUM 26.58% 1-Year Est. Return

Sharkey, Howes & Javer's TEVA Position: Q3 2019 in Review

Sharkey, Howes & Javer sold out of Teva Pharmaceuticals (TEVA) in Q3 2019, closing a stake of 750 shares — an estimated $7K sold.

Sharkey, Howes & Javer first reported a position in TEVA in Q1 2015 and held it in 18 quarters. The position peaked at $108K in Q4 2015. 428 funds tracked by Wall St. Rank hold TEVA as of Q3 2019.

Sharkey, Howes & Javer reported no remaining Teva Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
Sharkey, Howes & Javer sold 750 Teva Pharmaceuticals shares in Q3 2019, an estimated $7K.
Sharkey, Howes & Javer first reported a position in Teva Pharmaceuticals in Q1 2015 and held it in 18 quarters.
Sharkey, Howes & Javer's Teva Pharmaceuticals position peaked at $108K in Q4 2015.
428 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q3 2019.

Based on Sharkey, Howes & Javer's 13F filing for Q3 2019, filed 1 Nov 2019.